Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Combination of concomitant Radio-Chemotherapy showed a significant improvement (Takada) of OS
and PFS in limited disease SCLC patients. This clinical trial is a prospective, multicenter,
randomized, open-label, parallel group phase II investigator initiated trial (ITT) to
evaluate the efficacy and safety of Durvalumab in combination with
Cisplatin/Etoposide/Radiotherapy in patients with limited disease small-cell lung cancer
(SCLC).